17.53
Dianthus Therapeutics Inc stock is traded at $17.53, with a volume of 269.99K.
It is up +0.81% in the last 24 hours and down -19.22% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$17.39
Open:
$17.54
24h Volume:
269.99K
Relative Volume:
0.80
Market Cap:
$563.76M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.1626
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-4.86%
1M Performance:
-19.22%
6M Performance:
-31.79%
1Y Performance:
-18.88%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DNTH
Dianthus Therapeutics Inc
|
17.53 | 576.63M | 4.12M | -56.68M | -51.44M | -5.5429 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-20-24 | Initiated | TD Cowen | Buy |
Oct-03-24 | Initiated | Oppenheimer | Outperform |
Jul-26-24 | Initiated | Robert W. Baird | Outperform |
Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
May-16-24 | Initiated | H.C. Wainwright | Buy |
Feb-15-24 | Initiated | Stifel | Buy |
Dec-26-23 | Initiated | Jefferies | Buy |
Nov-22-23 | Initiated | Wedbush | Outperform |
Oct-30-23 | Initiated | Guggenheim | Buy |
Sep-28-23 | Initiated | Raymond James | Outperform |
Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
Aug-20-21 | Resumed | Goldman | Neutral |
Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-22-21 | Reiterated | B. Riley Securities | Buy |
Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-15-21 | Initiated | BTIG Research | Buy |
May-18-21 | Initiated | B. Riley Securities | Buy |
Jan-07-21 | Initiated | Mizuho | Buy |
Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLC - Defense World
BNP Paribas Financial Markets Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2%Time to Sell? - MarketBeat
Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00 - MarketBeat
Deutsche Bank AG Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - The Manila Times
Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan
Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Point72 Asset Management L.P. Reduces Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP - MarketBeat
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - citybiz
Dianthus Therapeutics appoints new board member - Investing.com Australia
Dianthus Therapeutics Announces Board Changes and Elections - TipRanks
Dianthus Therapeutics appoints new board member By Investing.com - Investing.com UK
Former Novartis-Acquired CEO Joins Dianthus Board Ahead of Critical Phase 2 Data - Stock Titan
Janus Henderson Group PLC Buys 136,314 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Raised by Octagon Capital Advisors LP - MarketBeat
Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Wedbush Research Analysts Raise Earnings Estimates for DNTH - Defense World
HC Wainwright Issues Positive Forecast for DNTH Earnings - Defense World
Tower Research Capital LLC TRC Sells 944 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1% Following Analyst Downgrade - Defense World
DNTH: HC Wainwright & Co. Reiterates Buy Rating with $40 Target - GuruFocus
DNTH Stock Target Price Lowered by Analyst Baird | DNTH Stock Ne - GuruFocus
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views - Benzinga
Wedbush Adjusts Price Target on Dianthus Therapeutics to $34 From $36, Maintains Outperform Rating - marketscreener.com
Dianthus (DNTH) Target Price Adjusted Amid Q1 Pipeline Update | - GuruFocus
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results - The Manila Times
Dianthus Therapeutics Reports Increased R&D Expenses - TipRanks
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Lifted by Braidwell LP - MarketBeat
Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - MSN
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):